Eptifibatide Acetate | CAS 148031-34-9 / 188627-80-7 | GP IIb/IIIa Inhibitor (Research Use Only) | Knowlux

Product Description

Eptifibatide Acetate, CAS 148031-34-9 (acetate salt) / 188627-80-7 (free peptide), is a synthetic cyclic heptapeptide glycoprotein IIb/IIIa receptor inhibitor supplied by Knowlux for laboratory research use. The sequence is Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2, with a disulfide bridge between the Mpr and Cys residues. The molecular formula is C35H49N11O9S2 and the molecular weight is 831.96 g/mol (free peptide basis). Each lot is released with a lot-specific COA, MSDS and analytical traceability.

CAS and Salt Form Clarification: Two registries are commonly cited for this product. CAS 188627-80-7 corresponds to the free peptide, while CAS 148031-34-9 corresponds to the acetate salt. Supplier listings frequently use these interchangeably, which can cause confusion when comparing specifications or pricing. Knowlux declares the salt basis and counter-ion content per lot on the COA. Buyers should confirm whether the quoted material is free peptide or acetate salt before procurement, as the acetate content affects the mass balance and peptide content calculation.

Product Parameters

Product Details

1. Overview

Eptifibatide is a cyclic heptapeptide derived from the disintegrin protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It functions as a selective and reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, blocking fibrinogen binding and thereby inhibiting platelet aggregation. While Eptifibatide is an approved therapeutic agent in clinical medicine (marketed as Integrilin), the material supplied under this specification is intended strictly for laboratory research use and is not for human administration. Knowlux supplies this compound as a research-grade peptide for pharmacological and analytical investigations.

2. Structural Profile

The peptide backbone comprises seven residues with a unique N-terminal mercaptopropionyl (Mpr) group and a homoarginine (Har) residue in place of the standard arginine. A disulfide bridge between Mpr1 and Cys6 creates the cyclic structure essential for receptor binding activity. The C-terminal amide protects against carboxypeptidase degradation. The presence of the Mpr group and the disulfide bridge distinguishes Eptifibatide from linear RGD-containing peptides and contributes to its high binding affinity for the GP IIb/IIIa receptor.

3. Research Applications

Published pharmacological characterizations describe the following research applications:

• GP IIb/IIIa receptor binding and platelet aggregation inhibition assays

• Reference standard development for HPLC and LC-MS analytical methods

• Antiplatelet drug pharmacology and mechanism-of-action studies

• Method validation for peptide purity and counter-ion analysis

These descriptions are derived from published research and are provided for scientific reference only. They do not constitute clinical guidance or dosing recommendations.

Quality Control

Supplier-reported purities for commercial lots range from 98% to 99.6%. One supplier COA for the acetate salt reports HPLC purity of 99.57%, total impurities of 0.6%, acetate content of 8.7%, and water content of 3.8%. A GuideChem supplier listing reports endotoxin <=5 EU/mg for a pharmaceutical-grade material. Note that some supplier listings show peptide content as low as 75.0%, which may reflect the inclusion of acetate counter-ion and water in the mass balance. Researchers should verify that reported peptide content is calculated on an anhydrous, acetate-free basis where assay performance is critical. Full COA, MSDS, and lot-specific chromatograms are issued with each shipment.

Solubility and Handling

Solubility: Eptifibatide Acetate is soluble in water at concentrations of at least 1 mg/mL, yielding a clear, colorless solution. It is also soluble in DMSO (approximately 14 mg/mL) and DMF (approximately 30 mg/mL) according to supplier data. Prepare solutions fresh and aliquot to avoid repeated freeze-thaw cycles.

Handling Precautions: Use powder-handling containment (glove box or fume hood with particulate control). Avoid inhalation of fine powder. Wear nitrile gloves, lab coat, and eye protection. Follow institutional chemical hygiene plans for research peptides.

Storage and Stability

Storage recommendations align with supplier technical sheets. The lyophilized powder is hygroscopic; equilibrate vials to room temperature before opening to prevent condensation. Protect from light. The disulfide bridge is sensitive to reducing agents; avoid contact with dithiothreitol (DTT) or mercaptoethanol during handling.

Documentation Support

Per lot: COA, MSDS, certificate of origin, HPLC chromatogram, and mass spectrometry data. Regulatory packages (specification summaries, audit support) and third-party inspection available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

FOR RESEARCH USE ONLY. NOT FOR HUMAN USE. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Eptifibatide is an approved medicinal product in certain jurisdictions for specific clinical indications; however, the material offered under this specification is research-grade and is not intended for clinical use. The purchaser is responsible for verifying product specifications against their specific research requirements and for compliance with all applicable institutional, local, and national regulations governing research chemical acquisition, storage, and use. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.